| ID | 10306 |
| Vaccine Name | CHIK-VLP |
| Disease Name | Chikungunya fever |
| Disease Classification | Exanthous |
| Virus Name | Chikungunya virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Virus like particle |
| Vaccine Status | Phase 2 |
| Manufacturer | Emergent BioSolutions |
| Year of Manufacturing | 2020 |
| Manufacturing Country | USA |
| Age | 18 - 45 years |
| Dosage | 2 doses on day 0, 29 |
| Administration Route | Parenteral or mucosal route |
| Adjuvant | Alhydrogel |
| Target Strain | CHIKV structural proteins (C, E3, E2, 6K, E1) |
| Description | NA |
| Approving Organisation | US FDA |
| Collaborating Organisation | National Institute of Health, PaxVax |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT03483961 |
| Reference Link | https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 |
| Additional Links | https://clinicaltrials.gov/ct2/show/NCT03483961
|